The company utilizes an innovative technology called A-TAP to develop a new class of biological drugs that block vasculogenic mimicry and angiogenesis. Their most advanced product candidate, Anti-EGFR-TAP, is in preclinical development for Triple Negative Breast Cancer, while a second candidate, Anti-HER2-TAP, is being developed for ovarian cancer. Synergys operates using a virtual business model, collaborating with academic partners and contract research organizations for the development of their therapeutic candidates. The company's management and scientific board consist of experienced scientists, life science executives, and oncologists. Founded in 2010, Synergys Biotherapeutics is based in Alamo, California.